Skip to main content
. 2022 Oct 5;66:110–117. doi: 10.1016/j.breast.2022.10.002

Table 3.

Summary of analysis on PINT2 regarding patient preference of s.c. versus i.v. trastuzumab.

Parameter Category Thigh
N = 110
N (%)
Abdominal wall N = 109
N (%)
Overall
N = 219
N (%)
p-value
In how far were irritations around the s.c. injection site a problem for you? very 2 (2.2) 0 (0.0) 2 (1.1) 0.033
a bit 23 (24.7) 11 (12.4) 34 (18.7)
never 68 (73.1) 78 (87.6) 146 (80.2)
missing 17 20 37
How often were the reactions a problem for you? only at the first and/or second administration 12 (54.5) 3 (20.0) 15 (40.5) 0.036
in most of the administrations 10 (45.5) 12 (80.0) 22 (59.5)
missing 88 94 182
How would you generally describe the s.c. administrations? very uncomfortable 1 (1.1) 7 (8.0) 8 (4.4) 0.014
a bit uncomfortable 17 (18.3) 7 (8.0) 24 (13.3)
acceptable 75 (80.6) 74 (84.1) 149 (82.3)
missing 17 21 38
Which method of administration caused the least pain? i.v. 20 (21.5) 11 (12.4) 31 (17.0) 0.010
s.c. 19 (20.4) 36 (40.4) 55 (30.2)
no difference 54 (58.1) 42 (47.2) 96 (52.7)
missing 17 20 37
Which method of administration caused less pain due to bruises around the injection site? i.v. 13 (14.0) 5 (5.7) 18 (9.9) 0.083
s.c. 9 (9.7) 15 (17.0) 24 (13.3)
no difference 71 (76.3) 68 (77.3) 139 (76.8)
missing 17 21 38

s.c., subcutaneous; i.v. intravenous.